A Widely Applicable Platform Technology

Optimizing AI for personalized medicine

PD Theranostics (PDTx) leverages proprietary workflows and methods utilizing imaging-based methodologies to diagnose and guide clinical decision making around specific targeted therapies and their efficacy in human disease states, including cancer, infectious diseases and complications of diabetes including diabetic foot ulcers

This will drive the development of an artificial intelligence (AI) driven theranostic that will guide both diagnostic and therapeutic decision making – involving the use of both unique tissue preparation kits and novel algorithms.

Our goal: Improve outcomes while reducing costs

This approach could be applied to any disease in which diagnosis rests on the histopathological analysis of tissue biopsies

PDTx’s platform will be designed to determine the severity of the disease, aid in the refining the pathological diagnosis and optimal treatment decisions.

PD Theranostics, Inc. (PDTx) leverages proprietary workflows and methods utilizing imaging-based methodologies to diagnose and guide clinical decision making around specific targeted therapies and their efficacy in human disease states, including cancer, infectious diseases and complications of diabetes including diabetic foot ulcers.

The lead program uses an artificial intelligence (AI) driven theranostic that will guide both diagnostic and therapeutic decision making – involving the use of both unique tissue preparation kits and novel algorithms.

This approach could be applied to any disease in which diagnosis rests on the histopathological analysis of tissue biopsies.

PDTx’s platform can determine the severity of the disease, aid in the refining the pathological diagnosis and allow for optimal treatment decisions. This will potentially help improve patient outcomes and reduce costs to the healthcare system.